login
Become a member
Quick Registration
Full Registration Benefits -
Free Homepages for Doctors
Free Homepages for Hospitals
Free Homepages for Medical Conference
Free Homepages for NGO's
Personal Health Record Creation
Access to all Medical Slides
Access to all Jobs & Products Sale
Recurrent Gliomas: Vorinostat Shows Anti-cancer Activity
June 04, 2007 at 6:12 PM
Drug News
Glioblastoma multiforme is a lethal primary brain tumor. The average survival of glioblastoma patients is 12-16 months. These tumors spread quickly to other parts of the brain, and because of this are difficult to treat and often recur. When the tumor recurs, treatment options are limited, and patients survive for an average of three to four months.
"Existing treatment interventions have minimal impact on the outcome of recurrent glioblastoma multiforme patients," Dr. Galanis says. "Using vorinostat to treat glioblastoma multiforme patients who have relapsed following surgery, radiation and chemotherapy, we found that 15 percent of the patients had no tumor recurrence for six months or longer following treatment initiation. The median overall survival of the patients enrolled on the trial was 5.7 months -- similar patient populations enrolled in prior NCCTG trials had a median overall survival of between 4 and 4.4 months."
This study was the first application of vorinostat in targeting brain cancer. Vorinostat is approved by the U.S. Food and Drug Administration (FDA) for the treatment of cutaneous T cell lymphoma in patients who have failed two or more systemic therapies.
|
|
|
 Comment & Contribute
|
Medwonders Health Network
- Health News Index
 | Quiz on Cancer Looking for information on cancer? Go through medindia's Cancer quiz. 
|
- News Quick Links
| News Categories: |
| » | Vivek Oberoi Says There is No Smoking on His Sets |
| » | Gasoigne Swaps Booze for Botox |
| » | Michelle Obama: Name of Olive Tree in Italy |
| » | Beyonce: Most Beautiful Women in the World |
| » | Robin Gibb Recovers from Coma Wakes Up to Cancer |
| More Celebrity News | |
|
